FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282930468> ?p ?o ?g. }

• W4282930468 endingPage "2611" @default.
• W4282930468 startingPage "2611" @default.
• W4282930468 abstract "Abstract Colorectal cancer (CRC) is a heterogeneous disease with a wide spectrum of clinical outcomes, from indolent resectable disease to aggressive-metastatic cases. Primary and acquired resistance limits the efficacy of available treatments, and the identification of effective drug combinations is needed to further improve patients' outcomes. We previously found that the NEDD8-activating enzyme inhibitor pevonedistat induced tumor stabilization in preclinical models of poorly differentiated, clinically aggressive CRC resistant to available therapies. To identify drugs that can be effectively combined with pevonedistat, we performed a drop-out loss-of-function synthetic lethality screening with an shRNA library covering 200 drug-target genes in four different CRC cell lines. Multiple screening hits were found to be involved in the EGFR signaling pathway, suggesting that, rather than inhibition of a specific gene, interference with the EGFR pathway at any level could be effectively leveraged for combination therapies based on pevonedistat. Exploiting both BRAF-mutant and RAS/RAF wild-type CRC models, we validated the therapeutic relevance of our findings by showing that combined blockade of NEDD8 and EGFR pathways led to increased growth arrest and apoptosis both in vitro and in vivo. Pathway modulation analysis showed that compensatory feedback loops induced by single treatments were blunted by the combinations. Our results suggested possible therapeutic opportunities in specific CRC clinical settings. We further focused on HER2 amplified CRC cells and we observed cooperation between pevonedistat and HER2/EGFR blockade by the trastuzumab + lapatinib combination -the current standard treatment for HER2-amplified CRC. In addition, to confirm cooperation in reducing colony formation in vitro, we explored the effect of pevonedistat on long-term persisters, i.e., cell surviving to several weeks of HER2/EGFR blockade. Interestingly, we observed a marked decrease of cell colonies when pevonedistat was added to persisters survived to three weeks of trastuzumab + lapatinib treatment. These results unveil the possibility of testing in vivo the addition of pevonedistat subsequently to tumor stabilization or reduction by HER2/EGFR blockade, to promote further tumor regression. Citation Format: Federica Invrea, Alessandro Carugo, Sabrina Arena, Alberto Bardelli, Giulio F. Draetta, Enzo Medico. The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2611." @default.
• W4282930468 created "2022-06-16" @default.
• W4282930468 creator A5035320829 @default.
• W4282930468 creator A5037541103 @default.
• W4282930468 creator A5050464171 @default.
• W4282930468 creator A5056194390 @default.
• W4282930468 creator A5064011158 @default.
• W4282930468 creator A5081947642 @default.
• W4282930468 date "2022-06-15" @default.
• W4282930468 modified "2023-10-07" @default.
• W4282930468 title "Abstract 2611: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer" @default.
• W4282930468 doi "https://doi.org/10.1158/1538-7445.am2022-2611" @default.
• W4282930468 hasPublicationYear "2022" @default.
• W4282930468 type Work @default.
• W4282930468 citedByCount "0" @default.
• W4282930468 crossrefType "journal-article" @default.
• W4282930468 hasAuthorship W4282930468A5035320829 @default.
• W4282930468 hasAuthorship W4282930468A5037541103 @default.
• W4282930468 hasAuthorship W4282930468A5050464171 @default.
• W4282930468 hasAuthorship W4282930468A5056194390 @default.
• W4282930468 hasAuthorship W4282930468A5064011158 @default.
• W4282930468 hasAuthorship W4282930468A5081947642 @default.
• W4282930468 hasConcept C121608353 @default.
• W4282930468 hasConcept C126322002 @default.
• W4282930468 hasConcept C143998085 @default.
• W4282930468 hasConcept C170493617 @default.
• W4282930468 hasConcept C2777329042 @default.
• W4282930468 hasConcept C2778468042 @default.
• W4282930468 hasConcept C2779786085 @default.
• W4282930468 hasConcept C2781187634 @default.
• W4282930468 hasConcept C502942594 @default.
• W4282930468 hasConcept C526805850 @default.
• W4282930468 hasConcept C530470458 @default.
• W4282930468 hasConcept C71924100 @default.
• W4282930468 hasConceptScore W4282930468C121608353 @default.
• W4282930468 hasConceptScore W4282930468C126322002 @default.
• W4282930468 hasConceptScore W4282930468C143998085 @default.
• W4282930468 hasConceptScore W4282930468C170493617 @default.
• W4282930468 hasConceptScore W4282930468C2777329042 @default.
• W4282930468 hasConceptScore W4282930468C2778468042 @default.
• W4282930468 hasConceptScore W4282930468C2779786085 @default.
• W4282930468 hasConceptScore W4282930468C2781187634 @default.
• W4282930468 hasConceptScore W4282930468C502942594 @default.
• W4282930468 hasConceptScore W4282930468C526805850 @default.
• W4282930468 hasConceptScore W4282930468C530470458 @default.
• W4282930468 hasConceptScore W4282930468C71924100 @default.
• W4282930468 hasIssue "12_Supplement" @default.
• W4282930468 hasLocation W42829304681 @default.
• W4282930468 hasOpenAccess W4282930468 @default.
• W4282930468 hasPrimaryLocation W42829304681 @default.
• W4282930468 hasRelatedWork W1964065629 @default.
• W4282930468 hasRelatedWork W1967506091 @default.
• W4282930468 hasRelatedWork W2166148619 @default.
• W4282930468 hasRelatedWork W2167587342 @default.
• W4282930468 hasRelatedWork W2262572336 @default.
• W4282930468 hasRelatedWork W2333897269 @default.
• W4282930468 hasRelatedWork W2509762766 @default.
• W4282930468 hasRelatedWork W2530207093 @default.
• W4282930468 hasRelatedWork W2989981638 @default.
• W4282930468 hasRelatedWork W67104293 @default.
• W4282930468 hasVolume "82" @default.
• W4282930468 isParatext "false" @default.
• W4282930468 isRetracted "false" @default.
• W4282930468 workType "article" @default.